ClinicalTrials.gg
RecruitingNCT04723888Updated Feb 21, 2021

Alpha-Ketoglutarate and Abdominal Aortic Aneurysm Progression and Rupture

An interventional study of alpha-ketoglutarate in Patients With an Abdominal Aortic Aneurysm of 39-49 mm in Diameter, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Aortic Aneurysm, Abdominal with a site in China — 7 open to participants now, 9 under way, none of them phase 3. Aortic Aneurysm, Abdominal · China.

Started
2021
the only one that year
No phase
8 of 17
2 open now
Registered
8th of 17
by date
Lead sponsor
4 of 17
RenJi Hospital

Among the 17 studies in Aortic Aneurysm, Abdominal with a site in China, this one is the only one that started in 2021, is one of 8 with no phase, and was the 8th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

7 of the 17 studies in Aortic Aneurysm, Abdominal with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Aortic Aneurysm, Abdominal with a site in China, or all of them as a file.
02

Study summary

The objective of this project is to define whether nutritional supplement (oral administration with alpha-ketoglutarate) capable of filling-up the citric acid cycle (anaplerotic therapy) can improve outcomes in patients with an abdominal aortic aneurysm of 39-49 mm in diameter on ultrasound imaging. Alpha-ketoglutarate is commonly used as a nutritional supplement specially by athletes to increase muscle strength. They can be mixed with formula or other foods. Subjects will be followed for up to 5 years.

Read the detailed description

Abdominal aortic aneurysm (AAA) is an age-related disease that characterized by permanent regional dilation of the abdominal aortae, which results in catastrophic event of rupture and sudden death. Currently, no effective drug to limit the progression or reduce the risk of rupture has been developed.

Metabolic pathways, including glucose metabolism, lipid metabolism, and amino acid metabolism, have indispensable roles in normal and dysfunctional vasculature. The Krebs cycle is responsible for obtaining energy from food in the form of ATP, and ATP is essential for muscle contraction and correct functioning of all organs. Besides, tight control of mitochondrial functions is critical for maintaining metabolism balance.

As an important metabolite in Krebs cycle, alpha-ketoglutarate not only improved energy metabolism, but also extended lifespan and reduced morbidity in aging mice. It is widely used in the market as a nutritional supplement specially by athletes to increase muscle strength. Until now, no obvious toxic and side effects to the body was observed. Given the high bioavailability, we propose that dietary supplementation with alpha-ketoglutarate can improve the outcome in patients with an abdominal aortic aneurysm of 39-49 mm in diameter.

Therefore, the project team intends to establish the abdominal aortic aneurysm rupture risk prediction model in the elderly cohort in the early stage, and randomize groups in patients with an abdominal aortic aneurysm of 39-49 mm in diameter based on whether or not to supplement alpha-ketoglutarate. There are two cohorts: the alpha-ketoglutarate intervention cohort and the parallel control cohort. By observing the efficacy in terms of change in aortic diameter and abdominal aortic aneurysm rupture incidence in the two groups during the follow-up period, it provides evidence-based medical evidence for the future clinical application of alpha-ketoglutarate.

03

Conditions studied

  • Patients With an Abdominal Aortic Aneurysm of 39-49 mm in Diameter

Keywords

  • cohort study
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Presence of an infrarenal AAA with a maximum diameter of 39-49 mm;
  2. Han nationality;
  3. Between 50 years or more, no gender limit;
  4. No mental illness;
  5. No history of supplement allergy or supplement allergy;
  6. Subjects voluntarily participate in this study, sign an form, have good compliance, and cooperate with follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Previous infrarenal aortic surgery;
  2. Planned major surgery;
  3. Known aortic dissection;
  4. Have received any other clinical trial treatment within 1 year;
  5. Systemic treatment with or other systemic immunomodulatory therapy;
  6. Severe infections, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.;
  7. Known or suspected inherited connective tissue disorder;
  8. Calculated of less than 30 ml/min;
  9. Known significant liver disease;
  10. Known infection at the time of screening;
  11. Serious concomitant illness associated with of less than 2 years;
  12. Any other significant and unstable condition that could limit compliance with the trial protocol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    alpha-ketoglutarate Group

    Take alpha-ketoglutarate supplements, alpha-ketoglutarate 300mg/d mixed with food or drink, for 1 years

    Dietary Supplement: alpha-ketoglutarate

  • No intervention
    Normal Control Group

    Don't take alpha-ketoglutarate supplements

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in aortic diameter

    Measure the aortic diameter by ultrasound imaging from leading edge adventitia at the anterior wall to leading edge adventitia at the posterior wall.

    Time frame: 1 year

Secondary outcomes

  1. Rates of AAA repair/rupture

    Calculate the incidence of AAA repair/rupture

    Time frame: 1 year

  2. Rates of mortality

    Calculate the mortality due to AAA rupture

    Time frame: 1 year

  3. Changes level of plasma biomarker

    Measure plasma levels of tryptase

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2026, 60 months after the start.

Of 51 non-industry interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's planned 60 months is above that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2021
First posted
Jan 26, 2021
StartActual
Feb 1, 2021
Primary completionEst.
Feb 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04723888
Lead sponsor
RenJi Hospital
Responsible party
Jun Pu (Director of Cardiovascular Medicine, RenJi Hospital) — Principal investigator
First posted
Jan 26, 2021
Start date
Feb 1, 2021
Primary completion
Feb 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 21, 2021

Study contacts

Jun Pu
Contact
pujun310@hotmail.com
86-21-68383477
Jun Pu
principal investigator · RenJi Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketoglutaric Acids

Start the discussion